Moderna Inc

14 sept. 2026, 20:08 UTC

Moderna Inc shows upward momentum as social media discussions highlight low selling volume and consolidation above $130, suggesting potential for a breakout.

11 sept. 2026, 19:53 UTC

Moderna Inc shares are advancing, reaching $147.59 amid strong options demand and bullish sentiment, despite pulling back earlier in the session.

10 sept. 2026, 23:01 UTC

Moderna Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock had previously shown significant gains.

8 sept. 2026, 19:46 UTC

Moderna Inc shares are lower following a downgrade to Sell from Rothschild & Co Redburn, now trading near $142.95.

4 sept. 2026, 20:08 UTC

Moderna Inc. shares are lower, facing resistance below $147. A recent $2.6 billion convertible notes offering may be impacting trading sentiment.

3 sept. 2026, 23:05 UTC

Moderna Inc shares declined after-hours, reversing earlier gains despite broader market strength. No specific news was identified to explain the movement.

2 sept. 2026, 20:08 UTC

Moderna Inc. shares are lower as investors take profits after a significant gain. Analysts note critical resistance around $162 amid concerns of overbought conditions.

1 sept. 2026, 23:01 UTC

Moderna Inc shares declined in after-market trading, reversing a trend of higher daily closes amid speculation on its bird flu vaccine development.

31 aug. 2026, 23:01 UTC

Moderna Inc. shares are lower in after-market trading amid broader market pressure from hawkish comments by Federal Reserve Chair Kevin Warsh.

29 aug. 2026, 00:02 UTC

Moderna Inc. shares are lower in after-market hours, marking a fourth consecutive decline. Broader market dynamics may be influencing investor sentiment.

28 aug. 2026, 23:01 UTC

Moderna Inc shares are lower in after-market trading, continuing a trend of four consecutive daily declines without any specific news driving the movement.

27 aug. 2026, 23:02 UTC

Moderna Inc shares are lower in after-market trading as broader market trends weigh on performance, despite FDA approval of updated COVID-19 vaccine formulas.

26 aug. 2026, 23:02 UTC

Moderna Inc. shares are lower in after-market trading, breaking from a recent trend of higher daily closes. No specific news has been identified.

25 aug. 2026, 23:06 UTC

Wolfe Research upgraded Moderna to Peer Perform, citing positive melanoma trial results and estimating peak sales potential at $9.2 billion. Shares are higher in after-market hours.

24 aug. 2026, 20:02 UTC

Moderna Inc. shares are lower today despite positive data on its mRNA cancer vaccine, which showed efficacy when combined with Merck's Keytruda.

21 aug. 2026, 23:36 UTC

Moderna Inc. shares are higher in after-market trading following a successful melanoma trial, reflecting strong investor interest and elevated trading volume.

20 aug. 2026, 23:01 UTC

Moderna Inc. shares are lower in after-market trading amid skepticism about its mRNA cancer vaccine and broader declines in U.S. stocks following Walmart's poor performance.

19 aug. 2026, 23:51 UTC

Moderna shares lower in after-market trading despite positive Phase 3 results for its mRNA cancer vaccine, which boosted market cap by over $50 billion.

18 aug. 2026, 23:51 UTC

MAHA shares are lower in after-market trading amid growing disappointment over the FDA's approval of Moderna's mRNA flu shot and recent departures from the agency.

17 aug. 2026, 20:06 UTC

Concerns about the FDA's approval of Moderna's flu vaccine persist. Shares are higher today, remaining above the 20-day moving average.

14 aug. 2026, 23:51 UTC

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

13 aug. 2026, 23:21 UTC

Moderna's first mRNA flu shot receives FDA approval, despite concerns over a high adverse reaction rate. Shares are higher in after-market trading.

12 aug. 2026, 23:51 UTC

Moderna Inc shares are lower in after-market hours with no specific news identified. Recent easing inflation has influenced broader market sentiment.

10 aug. 2026, 19:36 UTC

The FDA has approved Moderna's mRNA flu vaccine for adults 50 and older. Shares are advancing modestly amid concerns over safety and efficacy.

7 aug. 2026, 19:52 UTC

The FDA approved Moderna's mRNA flu vaccine, mFlusiva, for adults 50 and older. Shares are higher during Friday's trading session.

6 aug. 2026, 23:06 UTC

Moderna's mRNA flu vaccine, "mFlusiva," receives FDA approval for adults aged 50 to 64, boosting shares higher in after-market trading.

5 aug. 2026, 19:46 UTC

Moderna Inc. shares are lower as disappointing ADP employment data weighs on market sentiment. The FDA has set a decision date for its mFlusiva vaccine.

4 aug. 2026, 20:07 UTC

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3 aug. 2026, 20:03 UTC

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31 iul. 2026, 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.